China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight ...
Reuters noted that Novo Nordisk is preparing for its weight-loss drug Wegovy to be approved in China this year, with an anticipated limited launch. Additionally, Eli Lilly is co-developing another ...
China alone, the market is expected to grow to 14.9 billion yuan ($2 billion) by 2030. The approval is potentially paving the way for off-label use of Tirzepatide for weight loss, similar to Wegvoy.
, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk (NOVOb.CO ...
Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market ...
Shares of the drugmaker were up 3.2% in early trading. Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are ...
Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes. Tirzepatide, a novel dual agonist at both the GLP-1 and the glucose-dependent ...
Benzinga - by Vandana Singh, Benzinga Editor. On Tuesday, Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval sets the stage ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in ...